IllnessOvarian cancer / PARP inhibitor therapy

NGS +

Sanger

Mutations in the BRCA1/2 genes are associated with improved treatment response in ovarian cancer patients (1, 2). In the randomized Phase 2 trial 19 (https://www.clinicaltrials.gov/ct2/show/NCT00753545), olaparib maintenance therapy significantly delayed disease progression in patients with metastatic ovarian cancer and BRCA1/2 mutations, progression-free survival was increased from 4.3 months (placebo) to 11.2 months (olaparib) (1, 3). In a randomized Phase 3 study (SOLO1), it was shown that patients with BRCA1/2 mutated advanced high-grade ovarian cancer also benefit from olaparib maintenance therapy in first-line treatment (4, 5). Olaparib has therefore also been approved for the maintenance treatment of advanced or progressive high-grade epithelial ovarian cancer. Somatic mutations are detected in 6% of patients with ovarian cancer, which is also an indication for therapy according to the European EMA approval.

Reference: (1) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70228-1/fulltext

(2) https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186043

(3) https://www.awmf.org/uploads/tx_szleitlinien/032-035OLk_S3_Ovarialkarzinom_2020-04.pdf

(4) https://www.dgho.de/publikationen/stellungnahmen/fruehe-nutzenbewertung/olaparib/olaparib-dgho-stellungnahme-20150922.pdf

(5) https://www.nejm.org/doi/full/10.1056/NEJMoa1810858

• Alias: Olaparib-Therapie
• Alias: Ovarial-Ca (Behandlung mit PARP-Inhibitoren)
• Alias: Ovarial-Karzinom (BRCA1, BRCA2); Therapie
• Ovarian carcinoma (BRCA1, BRCA2) - Olaparib therapy